Rotigotine for the treatment of Parkinson’s disease

References

• DeStefano AL, Lew MF, Golbe LI et al. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am. J. Hum. Genet.70(5), 1089–1095 (2002).
   PubMed Web of Science ®Google Scholar
• Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology52(6), 1214–1220 (1999).
   PubMed Web of Science ®Google Scholar
• Huse DM, Schulman K, Orsini L et al. Burden of illness in Parkinson’s disease. Mov. Disord.20(11), 1449–1454 (2005).
   PubMed Web of Science ®Google Scholar
• Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med.276(7), 374–379 (1967).
   PubMed Web of Science ®Google Scholar
• Shaunak S, Wilkins A, Pilling JB, Dick DJ. Pericardial, retroperitonel and pleural fibrosis induced by pergolide. J. Neurol. Neurosurg. Psychiatr.66(1), 79–81 (1999).
   PubMed Web of Science ®Google Scholar
• Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin. Proc.77(12), 1280–1286 (2002).
   PubMed Web of Science ®Google Scholar
• Management of Parkinson’s disease: an evidence-based review. Mov. Disord.17(Suppl. 4), S1–S166 (2002).
   PubMedGoogle Scholar
• Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology58(1), 11–17 (2002).
   PubMed Web of Science ®Google Scholar
• Eisler T, Eng N, Plotkin C, Calne DB. Absorption of levodopa after rectal administration. Neurology31(2), 215–217 (1981).
   PubMed Web of Science ®Google Scholar
• Nausieda PA, Pfeiffer RF, Tagliati M et al. A multicenter, open-label, sequential study comparing preferences for carbidopa–levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson’s disease. Clin. Ther.27(1), 58–63 (2005).
   PubMed Web of Science ®Google Scholar
• Iyer SS, Morgan JC, Sethi KD. Absorption of orally-disintegrating carbidopa–levodopa requires intact small bowel function. Neurology65(9), 1507 (2005).
   PubMed Web of Science ®Google Scholar
• Clarke A, Brewer F, Johnson ES et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J. Neural Transm.110(11), 1241–1255 (2003).
   PubMed Web of Science ®Google Scholar
• Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM, Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord.19(4), 426–432 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. N. Engl. J. Med.328(3), 176–183 (1993).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch. Neurol.59(12), 1937–1943 (2002).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol.62(2), 241–248 (2005).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet365(9463), 947–954 (2005).
   PubMed Web of Science ®Google Scholar
• Beaulieu M, Itoh Y, Tepper P et al. N-disubstituted 2-aminotetralins are potent D-2 dopamine receptor agonists. Eur. J. Pharmacol.105(1–2), 15–21 (1984).
   PubMed Web of Science ®Google Scholar
• Timmerman W, Westerink BH, De Vries JB, Tepper PG, Horn AS. Microdialysis and striatal dopamine release: stereoselective actions of the enantiomers on N-0437. Eur. J. Pharmacol.162(1), 143–150 (1989).
   PubMed Web of Science ®Google Scholar
• Van der Weide J, Tendijck ME, Tepper PF, De Vries JB, Dubocovich ML, Horn AS. The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and post-synaptic dopamine receptors. Eur. J. Pharmacol.146(2–3), 319–326 (1988).
   PubMed Web of Science ®Google Scholar
• Jenner P. A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology65(2 Suppl. 1), S3–S5 (2005).
   PubMedGoogle Scholar
• Belluzzi JD, Domino EF, May JM, Bankiewicz KF, McAfee DA. N-0923, a selective D2 receptor agonist, is efficacious in rat and monkey models of Parkinson’s disease. Mov. Disord.9(2), 147–154 (1994).
   PubMed Web of Science ®Google Scholar
• Mucke HA. Rotigotine Schwarz Pharma. IDrugs6(9), 894–899 (2003).
   PubMed Web of Science ®Google Scholar
• Lebsanft HB, Scheller DKA, Heindl M et al. Effect of continuous administration of rotigotine in a rat model of dyskinesia. Mov. Disord.20(Suppl. 10), S89 (2005).
   PubMed Web of Science ®Google Scholar
• Schneider JC, McLaughlin WW, Roeltgen DP. Anti-Parkinson effects of the selective dopamine D-2 agonist N-0923 in hemi-Parkinsonian monkeys. Neurology42(4 Suppl. 3), 443 (1992).
   Web of Science ®Google Scholar
• Scheller DK. Neuroprotection by rotigotine: investigations in MPTP-lesioned mice under continuous dopaminergic stimulation. Ann. Neurol.56(Suppl. 8), S54 (2004).
   Google Scholar
• Stichel CC, Scheller DKA. Rotigotine prevents neurodegeneration in a mouse model of Parkinson’s disease. 9th Congress of the European Federation of Neurological Societies, Athens, Greece (2005) (Abstract 250).
   Google Scholar
• Swart PJ, de Zeeuw RA. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Pharmazie47(8), 613–615 (1992).
   PubMed Web of Science ®Google Scholar
• Swart PJ, de Zeeuw RA. Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienlethylamino)-5-hydroxyteralin in freely moving rats. J. Pharm. Sci.82(2), 200–203 (1993).
   PubMed Web of Science ®Google Scholar
• Calabrese VP, Lloyd KA, Brancazio P et al. N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism. Mov. Disord.13(5), 768–774 (1998).
   PubMed Web of Science ®Google Scholar
• Metman LV, Gillespie M, Farmer C et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson’s disease. Clin. Neuropharmacol.24(3), 163–169 (2001).
   PubMed Web of Science ®Google Scholar
• Güldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin. Neuropharmacol.28(3), 106–110 (2005).
   PubMed Web of Science ®Google Scholar
• Cawello W, Braun M, Horstmann R. Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function. J. Clin. Pharmacol.45(9), 1091(2005) (Abstract 102).
   Web of Science ®Google Scholar
• Watts RL, Wendt RL, Nausied B et al. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson’s disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial. Mov. Disord.19(Suppl. 9), S258 (2004).
   Google Scholar
• Braun M, Cawello W, Poole K et al. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson’s disease. 9th Congress of the European Federation of Neurological Societies, Athens, Greece (2005) (Abstract P1245).
   Google Scholar
• Swart PJ, Oelen WE, Bruins AP, Tepper PG, de Zeeuw RA. Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry. J. Anal. Toxicol.18(2), 71–77 (1994).
   PubMed Web of Science ®Google Scholar
• Hansen K, Braun M, Horstmann R. Low drug-drug interaction potential of rotigotine. J. Clin. Pharmacol.45(9), 1091 (2005) (Abstract 101).
   Web of Science ®Google Scholar
• Braun M, Cawello W, Horstmann R. Lack of pharmacokinetic interaction between the dopamine agonist rotigotine and levodopa/carbidopa. 16th International Congress on Parkinson’s Disease and Related Disorders, Berlin, Germany (2005) (Abstract 4775).
   Google Scholar
• Hutton JT, Metman LV, Chase TN et al. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson’s disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov. Disord.16(3), 459–463 (2001).
   PubMed Web of Science ®Google Scholar
• Bianchine J, Poole K, Woltering F. Efficacy and dose response of the novel transdermally applied dopamine agonist rotigotine CDS in early Parkinson’s disease. Neurology58(Suppl. 3), A162–A163 (2002).
   Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch. Neurol.60(12), 1721–1728 (2003).
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Nausieda PA, Chang F et al. Rotigotine transdermal system as adjunctive therapy to levodopa in patients with advanced-stage Parkinson’s disease. Results of a randomized, double-blind, placebo-controlled, multicenter, multinational trial. 18th World Congress of Neurology Meeting, Sydney, Australia (2005) (Abstract).
   Google Scholar
• Quinn N, for the SP511 Investigators. Rotigotine Transdermal Delivery System (TDS) (SP-962): a multi-center, double-blind, randomized, placebo-controlled trial to assess the safety and efficacy of rotigotine TDS in patients with advanced Parkinson’s disease. Parkinsonism Relat. Disord.7(Suppl. 1), S66 (2002).
   Google Scholar
• Giladi N, Tolosa E, Boothman B et al. Rotigotine transdermal system in patients with idiopathic Parkinson’s disease: results of two placebo- and comparator controlled trials. Late Breaking Abstract presented at the World Parkinson Congress, Washington, DC, February (2006).
   Google Scholar
• Poewe W, Giladi N, Boothman B et al. Rotigotine transdermal system in patients with advanced-stage Parkinson’s disease as adjunctive therapy to levodopa: results of a placebo- and pramipexole-controlled trial. Late Breaking Abstract presented at the World Parkinson Congress, Washington, DC, February (2006).
   Google Scholar
• Pfutzner W, Przybilla B. Malignant melanoma and levodopa: is there a relationship? Two new cases and a review of the literature. J. Am. Acad. Dermatol.37(2 Pt 2), 332–333 (1997).
   PubMed Web of Science ®Google Scholar
• Siple JF, Schneider DC, Wanlass WA, Rosenblatt BK. Levodopa therapy and the risk of malignant melanoma. Ann. Pharmacother.34(3), 382–385 (2000).
   PubMed Web of Science ®Google Scholar
• Leopold NA, Polanksy M, Hurka MR. Drug adherence in Parkinson’s disease. Mov. Disord.19(5), 513–517 (2004).
   PubMed Web of Science ®Google Scholar
• Bibbiani F, Constantini LC, Patel R, Chase TN. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp. Neurol.192(1), 73–78 (2005).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson’s disease. Trends Neurosci.23(Suppl. 10), S109–S115 (2000).
   PubMed Web of Science ®Google Scholar
• Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson’s disease. Trends Neurosci.23(10 Suppl.), S117–S126 (2000).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med.342(20), 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol.61(7), 1044–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch. Neurol.62(6), 905–910 (2005).
   PubMed Web of Science ®Google Scholar
• Lake Y, Pinnock S. Improved patient acceptability with a transdermal drug-in-adhesive oestradiol patch. Aust. NZ J. Obstet. Gynaecol.40(3), 313–316 (2000).
   PubMed Web of Science ®Google Scholar
• Stiasny-Kolster K, Kohnen R, Schollmayer E et al. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov. Disord.19(12), 1432–1438 (2004).
   PubMed Web of Science ®Google Scholar
• Foley P, Gerlach M, Double KL, Riederer P. Dopamine receptor agonists in the therapy of Parkinson’s disease. J. Neural Transm.111(10–11), 1375–1446 (2004).
   PubMed Web of Science ®Google Scholar